Psorinum, the anti cancer miracle from India.

Although, great advances have been made in the treatment of some forms of cancer and new advances in surgery, radiotherapy, and chemotherapy leading to an increase in cure rates have been achieved, such interventions are often too much expensive and beyond the reach of many cancer patients of the developing as well as of the developed countries. In developing countries, majority of the cancer patients have inadequate access to the mainstream cancer treatments due to lack of proper medical infrastructures, skills, and above all limited financial resources.

Some types of cancer (i.e., liver, gall bladder, pancreatic, and stomach) are still associated with poor prognosis to conventional cancer treatments.

 

Side effects of the chemotherapy and radiation therapy are also intolerable to many cancer patients. In most of the situations, elderly cancer patients cannot be provided with conventional cancer treatments because of old age-related problems . As a result, alternative cancer treatments have become an important feature of oncology regardless of geographic region and they appear to exist in greater abundance through out the world. Many alternative cancer therapeutic modalities are now being practiced in India, and one of them which has gained significant popularity is called Psorinum Therapy .

 

The investigational anticancer drug used in this alternative cancer therapy is “Psorinum” which is derived from the sphere of homeopathy. The supportive treatments of Psorinum Therapy are adopted both from the spheres of allopathy and homeopathy. Psorinum is an alcoholic extract of the scabies, slough, and pus cells. According to the pre-clinical data, “Psorinum-6x” (“x” stands for decimal potency of homeopathy) activates different immune effector cells (e.g., T cells, and accessory cells like, macrophages, dendritic cells, and natural killer cells) which can trigger a complex antitumor immune response . In a rat model study, daily oral administration of Psorinum 6x at doses up to 0.5ml/Kg body weight/day for 2 weeks resulted in no adverse side effect  Published retrospective and prospective studies also support the efficacy of Psorinum Therapy in treating patients with various malignancies.

 

In an observational, open level and single arm study on158 patients with histologically confirmed stomach, gall bladder, liver and pancreatic cancer, complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) of cases The participants' eligibility criteria included histopathology/cytopathology confirmation of malignancy, inoperable tumor, and no prior chemotherapy or radiation therapy. The primary outcome measures of the study were (i) to assess the radiological tumor response (ii) to find out how many participants survived at least 1 year, 2 years, 3 years, 4 years and finally 5 years after the beginning of the study considering each type of cancer. Psorinum-6x was administered orally to all the participants up to 0.02ml/Kg body weight as a single dose in empty stomach per day for 2 years along with allopathic and homeopathic supportive cares. There were 42 stomach cancers, 40 gall bladder cancers, 44 pancreatic cancers and 32 liver cancers included in the final analysis of the study. 

Some other homeopathic medicines were also used for supportive care:

 (5.95%) participants were dropped out from the study as they opted for conventional cancer treatments, among them 4 of stomach, 2 of gall bladder, 3 of pancreatic, and 1 of liver cancers.  Among the 158 participants, 84 (53.16%) were male and 74 (46.84%) were female. According to the AJCC TNM staging system, 39 (24.68%) were diagnosed at stage-III, and 112 (70.89%) were diagnosed at stage-IV. The participants' Karnofsky status was between 40–70%, and Eastern Cooperative Oncology Group (ECOG) status was between 2-3. Among the 39 participants (24.68%) who were diagnosed at stage-III, 13 (33.33%) had complete response and 16 (41.03%) had radiological partial response. Among the 112 (70.89%) participants who were diagnosed at stage-IV, 12 (10.71%) had radiological complete response and 38 (33.93%) had radiological partial response

 

In this study, no adverse side effects were observed from the drug Psorinum. However, very few patients reported to have mild oral irritation and skin itching which were successfully controlled by the supportive cares. Psorinum Therapy was also effective in improving the disease symptoms and the quality of life of the participants. At least 60% participants of stage-III and at least 45% participants of stage-IV reported that the therapy was effective in reducing their cancer-related pain, cough, dysponea, nausea and vomiting, fatigue, constipation and improving appetite, and weakness. These were also confirmed after examining the participants clinically. Improvements were also observed in the lab investigations like Complete Blood Count (CBC), Liver Function Test (LFT), Kidney function test, AFP level, and CA 19.9. These lab investigations were done as a part of their routine clinical check ups. Among the 158 participants, 98 (62.03%) were aged 65 years or more. Better outcomes were observed among the participants below 65 years of age than the participants who were over the age of 65. The outcomes did not vary significantly while considering gender.

Primary cancer types	No. of participants	TNM Staging of the participants		No. of patients: Complete tumor response occurred	No. of patients: Partial tumor response occurred
		Diagnosed at stage-II and stage-III	Diagnosed at stage-IV
Stomach	42	11	31	6 (14.29%)	16 (38.1%)
G. Bladder	40	13	27	7 (17.5%)	17 (42.5%)
Pancreas	44	9	35	8 (18.18%)	13 (29.55%)
Liver	32	13	19	7 (21.87%)	10 (31.25%)

Primary organ affected	No. of Patients	Male	Female	Survived at least 1 year	Survived at least 2 years	Survived at least 3 years	Survived at least 4 years	Survived at least 5 years
Stomach	42	22	20	34	24	21	20	16 (38.1%)
G. Bladder	40	21	19	32	25	20	18	15 (37.5%)
Pancreas	44	24	20	34	28	27	21	17 (38.64%)
Liver	32	17	15	26	22	19	17	14 (43.75%)

 

The cumulative 5-year survival was 39.24% for patients who received Psorinum treatment, compared with an estimated 5-year survival of 23% for stomach cancer, 10% for liver cancer, <4% for pancreatic cancer and <15% for gall bladder cancer for patients taking conventional therapies. 28 patients (17.72%) had a complete recovery from their cancer in this study.

 

Psorinum in the treatment of Non Small Cell Lung Cancer(NSCLC)
In another phase II, open-level, single arm, and single stage  study, also performed by Dr Chatterje et al, 95 participants were included with NSCLC.
According to the AJCC TNM staging system, 58 (61.05%) of them diagnosed at stage IV. According to the RECIST criteria, complete tumor
response occurred in 19 (20%) cases and partial tumor response occurred in 28 (29.47%) cases. 82 (86.32%) of them survived at least 1 yr, 70
(73.68%) survived at least 2 yrs, 58 (61.05%) survived at least 3 yrs, 49 (51.58%) survived at least 4 yrs, and 42 (44.21%) of them survived at
least 5 yrs. These participants did not receive chemotherapy, radiation therapy, or any other investigational cancer treatments. Participants
reported no side effects from the drug psorinum.

 

44 patients participated in the study with Psorinum D6, 0,02 ml per kg body weight in the morning on empty stomach. Survival after first year 34,
after 2 years 28, after 3 years 27, after 4 years 21, and after 5 years 17 of the patients were still alive, equal to a 5-year survival of 39% - Probably the highest ever recorded 5 yearr survival on Pancreatic  Cancer published so far in medicine history!!
These results were examined by a very critical an independent expert commission at the National Cancer Institute in Bethesda, near Washington DC, USA, who has accepted the results, so that Dr. Chatterjee was able to present the results at the ASCO conference. There are plans to make more research on Psorinum on the famous MD Andersson Cancer Institute in Houston,  Texas, USA
The treatment is suitable for many more cancer types, but research has so far been focused on the more difficult cancers.